Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
企業コードMRKR
会社名Marker Therapeutics Inc
上場日Nov 08, 2016
設立日2018
最高経営責任者「CEO」Dr. Juan F. Vera, M.D.
従業員数5
証券種類Ordinary Share
決算期末Nov 08
本社所在地2450 Holcombe Blvd
都市HOUSTON
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号77021
電話番号17134006400
ウェブサイトhttps://markertherapeutics.com/
企業コードMRKR
上場日Nov 08, 2016
設立日2018
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし